Hyperglycemia in non-obese patients with type 2 diabetes is associated with low muscle mass: The Multicenter Study for Clarifying Evidence for Sarcopenia in Patients with Diabetes Mellitus - PubMed (original) (raw)
Multicenter Study
. 2019 Nov;10(6):1471-1479.
doi: 10.1111/jdi.13070. Epub 2019 Jun 1.
Yasuharu Tabara 2, Hiroshi Ikegami 3, Yasunori Takata 4, Kei Kamide 5, Tome Ikezoe 6, Eri Kiyoshige 5, Yukako Makutani 3, Hiroshi Onuma 7, Yasuyuki Gondo 8, Kazunori Ikebe 9, Noriaki Ichihashi 6, Tadao Tsuboyama 6 10, Fumihiko Matsuda 2, Katsuhiko Kohara 11, Mai Kabayama 5, Masahiro Fukuda 12, Tomohiro Katsuya 13 14, Haruhiko Osawa 4, Yoshihisa Hiromine 3, Hiromi Rakugi 1
Affiliations
- PMID: 31074209
- PMCID: PMC6825926
- DOI: 10.1111/jdi.13070
Multicenter Study
Hyperglycemia in non-obese patients with type 2 diabetes is associated with low muscle mass: The Multicenter Study for Clarifying Evidence for Sarcopenia in Patients with Diabetes Mellitus
Ken Sugimoto et al. J Diabetes Investig. 2019 Nov.
Abstract
Aims/introduction: Hyperglycemia is a risk factor for sarcopenia when comparing individuals with and without diabetes. However, no studies have investigated whether the findings could be extrapolated to patients with diabetes with relatively higher glycemic levels. Here, we aimed to clarify whether glycemic control was associated with sarcopenia in patients with type 2 diabetes.
Materials and methods: Study participants consisted of patients with type 2 diabetes (n = 746, the average age was 69.9 years) and an older general population (n = 2,067, the average age was 68.2 years). Sarcopenia was defined as weak grip strength or slow usual gait speed and low skeletal mass index.
Results: Among patients with type 2 diabetes, 52 were diagnosed as having sarcopenia. The frequency of sarcopenia increased linearly with glycated hemoglobin (HbA1c) level, particularly in lean individuals (HbA1c <6.5%, 7.0%, ≥6.5% and <7.0%: 18.5%; HbA1c ≥7.0% and <8.0%: 20.3%; HbA1c ≥8.0%: 26.7%). The linear association was independent of major covariates, including anthropometric factors and duration of diabetes (HbA1c <6.5%: reference; ≥6.5% and <7.0%: odds ratio [OR] 4.38, P = 0.030; HbA1c ≥7.0% and <8.0%: 4.29, P = 0.024; HbA1c ≥8.0%: 7.82, P = 0.003). HbA1c level was specifically associated with low skeletal mass index (HbA1c ≥8.0%: OR 5.42, P < 0.001) rather than weak grip strength (OR 1.89, P = 0.058) or slow gait speed (OR 1.13, P = 0.672). No significant association was observed in the general population with a better glycemic profile.
Conclusions: Poor glycemic control in patients with diabetes was associated with low muscle mass.
Keywords: Sarcopenia; Skeletal muscle mass; Type 2 diabetes.
© 2019 The Authors. Journal of Diabetes Investigation published by Asian Association for the Study of Diabetes (AASD) and John Wiley & Sons Australia, Ltd.
Figures
Figure 1
Association between glycated hemoglobin (HbA1c) levels and sarcopenia in patients with type 2 diabetes. The frequency of sarcopenia by body mass index and plasma HbA1c levels. Study participants were subdivided at a body mass index (BMI) of 25 kg/m2, a criterion of obesity in Japan, and 23.3 kg/m2, which corresponds to the median among the remaining non‐obese participants. The numbers of participants in each BMI subgroup are shown in the columns and parentheses.
Figure 2
Adjusted odds ratio for sarcopenia in non‐obese patients. (a) General population (the Nagahama study). (b) Patients with type 2 diabetes. Patients whose body mass index was >25 kg/m2 were excluded from the analysis. The odds ratio adjusted for age, sex and body mass index was calculated using the (a) intermediate or (b) lowest glycated hemoglobin (HbA1c) subgroup as a reference. T2DM, type 2 diabetes.
Similar articles
- Association of accumulated advanced glycation end-products with a high prevalence of sarcopenia and dynapenia in patients with type 2 diabetes.
Mori H, Kuroda A, Ishizu M, Ohishi M, Takashi Y, Otsuka Y, Taniguchi S, Tamaki M, Kurahashi K, Yoshida S, Endo I, Aihara KI, Funaki M, Akehi Y, Matsuhisa M. Mori H, et al. J Diabetes Investig. 2019 Sep;10(5):1332-1340. doi: 10.1111/jdi.13014. Epub 2019 Feb 19. J Diabetes Investig. 2019. PMID: 30677242 Free PMC article. - Glycemic Control and Insulin Improve Muscle Mass and Gait Speed in Type 2 Diabetes: The MUSCLES-DM Study.
Sugimoto K, Ikegami H, Takata Y, Katsuya T, Fukuda M, Akasaka H, Tabara Y, Osawa H, Hiromine Y, Rakugi H. Sugimoto K, et al. J Am Med Dir Assoc. 2021 Apr;22(4):834-838.e1. doi: 10.1016/j.jamda.2020.11.003. Epub 2020 Dec 2. J Am Med Dir Assoc. 2021. PMID: 33278348 - Poor glycemic control rather than types of diabetes is a risk factor for sarcopenia in diabetes mellitus: The MUSCLES-DM study.
Hiromine Y, Noso S, Rakugi H, Sugimoto K, Takata Y, Katsuya T, Fukuda M, Akasaka H, Osawa H, Tabara Y, Ikegami H. Hiromine Y, et al. J Diabetes Investig. 2022 Nov;13(11):1881-1888. doi: 10.1111/jdi.13882. Epub 2022 Jul 18. J Diabetes Investig. 2022. PMID: 35796583 Free PMC article. - Multi-level Analysis of HbA1c in Diagnosis and Prognosis of Diabetic Patients.
Mukherjee S, Ray SK, Jadhav AA, Wakode SL. Mukherjee S, et al. Curr Diabetes Rev. 2024;20(7):e251023222697. doi: 10.2174/0115733998262501231015051317. Curr Diabetes Rev. 2024. PMID: 37921158 Review. - The Impact of Glucose-Lowering Drugs on Sarcopenia in Type 2 Diabetes: Current Evidence and Underlying Mechanisms.
Massimino E, Izzo A, Riccardi G, Della Pepa G. Massimino E, et al. Cells. 2021 Aug 1;10(8):1958. doi: 10.3390/cells10081958. Cells. 2021. PMID: 34440727 Free PMC article. Review.
Cited by
- Prediabetes and diabetes were attributed to the prevalence and severity of sarcopenia in middle-aged and elderly adults.
Yuan J, Jia P. Yuan J, et al. Diabetol Metab Syndr. 2024 Jun 2;16(1):122. doi: 10.1186/s13098-024-01355-3. Diabetol Metab Syndr. 2024. PMID: 38825679 Free PMC article. - Significance of body mass index for diagnosing sarcopenia is equivalent to slow gait speed in Japanese individuals with type 2 diabetes: Cross-sectional study using outpatient clinical data.
Nakanishi S, Iwamoto M, Shinohara H, Iwamoto H, Kaneto H. Nakanishi S, et al. J Diabetes Investig. 2021 Mar;12(3):417-424. doi: 10.1111/jdi.13366. Epub 2020 Aug 11. J Diabetes Investig. 2021. PMID: 32686339 Free PMC article. - The Impact of Antidiabetic Agents on Sarcopenia in Type 2 Diabetes: A Literature Review.
Wu CN, Tien KJ. Wu CN, et al. J Diabetes Res. 2020 Jul 9;2020:9368583. doi: 10.1155/2020/9368583. eCollection 2020. J Diabetes Res. 2020. PMID: 32695832 Free PMC article. Review. - Reduced Skeletal Muscle Volume and Increased Skeletal Muscle Fat Deposition Characterize Diabetes in Individuals after Pancreatitis: A Magnetic Resonance Imaging Study.
Modesto AE, Ko J, Stuart CE, Bharmal SH, Cho J, Petrov MS. Modesto AE, et al. Diseases. 2020 Jul 1;8(3):25. doi: 10.3390/diseases8030025. Diseases. 2020. PMID: 32630360 Free PMC article. - Alterations in the structural characteristics of rectus abdominis muscles caused by diabetes and pregnancy: A comparative study of the rat model and women.
Vesentini G, Barbosa AMP, Damasceno DC, Marini G, Piculo F, Matheus SMM, Hallur RLS, Nunes SK, Catinelli BB, Magalhães CG, Costa R, Abbade JF, Corrente JE, Calderon IMP, Rudge MVC; DIAMATER Study Group. Vesentini G, et al. PLoS One. 2020 Apr 3;15(4):e0231096. doi: 10.1371/journal.pone.0231096. eCollection 2020. PLoS One. 2020. PMID: 32243473 Free PMC article.
References
- Chen LK, Liu LK, Woo J, et al Sarcopenia in Asia: consensus report of the Asian Working Group for Sarcopenia. J Am Med Dir Assoc 2014; 15: 95–101. - PubMed
- Park SW, Goodpaster BH, Strotmeyer ES, et al Decreased muscle strength and quality in older adults with type 2 diabetes: the health, aging, and body composition study. Diabetes 2006; 55: 1813–1818. - PubMed
Publication types
MeSH terms
Substances
Grants and funding
- 17H04182, 17H04126/Grant-in-Aid for Scientific Research
- ek0210066, ek0210096/Japan Agency for Medical Research and Development
- 2510211, 15K08910, 16K12336/Japan Science and Technology Agency
- ek0109070, ek0109070, ek0109196, ek0109348/Japan Science and Technology Agency
- dk0207006/Comprehensive Research on Aging and Health Science Research Grants for Dementia
- kk0205008/Program for an Integrated Database of Clinical and Genomic Information